Table 5.
Correlation of change between outcome measures
| EQ-5D | SF-6D | DAS28 | HAQ | EQ-VAS | 28 Tender | 28 Swollen | ESR | ||
|---|---|---|---|---|---|---|---|---|---|
| STIVEA | EQ-5D | – | 0.48 | −0.40 | −0.53 | −0.52 | −0.27 | −0.04 | −0.35 |
| SF-6D | 0.48 | – | −0.50 | −0.67† | −0.59 | −0.34 | −0.16 | −0.31 | |
| BROSG (3-year) | EQ-5D | – | 0.38 | −0.16 | −0.28 | 0.26 | −0.11 | 0.08 | −0.18 |
| SF-6D | 0.38 | – | −0.17 | −0.36 | 0.32 | −0.10 | 0.01 | −0.23 | |
| BROSG(D) (1 year) | EQ-5D | – | 0.25 | −0.16 | −0.14 | 0.16 | −0.03 | −0.13 | −0.11 |
| SF-6D | 0.25 | – | −0.29 | −0.24 | 0.31 | −0.04 | −0.11 | −0.12 | |
| BROSG(I) (1 year) | EQ-5D | – | 0.37 | −0.17 | −0.31 | 0.19 | −0.16 | −0.03 | 0.01 |
| SF-6D | 0.37 | – | −0.37† | −0.20 | 0.32 | −0.18 | −0.25† | −0.16 | |
| BSRBR | EQ-5D | – | 0.44 | −0.16 | −0.37 | 0.41 | −0.14 | −0.07 | 0.01 |
| SF-6D | 0.44 | – | −0.34 | −0.64†† | 0.48 | −0.28 | −0.23† | 0.04 | |
| BSRBR control | EQ-5D | – | 0.38 | −0.16 | −0.22 | 0.26 | – | – | – |
| SF-6D | 0.38 | – | −0.23 | −0.21 | 0.26 | – | – | – |
BROSG(D) = EQ-VAS score worse (>20 & <50%) than baseline; BROSG(I) = EQ-VAS score better (>20 & <50%) than at baseline
EQ-5D EuroQol-5D, SF-6D Short Form-6D, EQ-VAS EuroQol Visual Analogue Scale, STIVEA steroids in very early arthritis, BROSG British Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, HAQ Health Assessment Questionnaire, DAS28 Disease Activity Score based on 28 swollen joint counts, ESR erythrocyte sedimentation rate, s.d. standard deviation
Steiger’s Z-test: † P < 0.05; †† P < 0.01